[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @drughunter_com drug hunter drug hunter posts on X about novartis, $4521t, $40m, $ptct the most. They currently have XXXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1366500304867401729/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +218% - X Months XXXXXXX +86% - X Year XXXXXXX +129% ### Mentions: X [#](/creator/twitter::1366500304867401729/posts_active)  - X Week XX +71% - X Month XX +120% - X Months XX +19% - X Year XXX +159% ### Followers: XXXXXX [#](/creator/twitter::1366500304867401729/followers)  - X Week XXXXXX +0.13% - X Month XXXXXX +0.72% - X Months XXXXXX +5.50% - X Year XXXXXX +7.30% ### CreatorRank: undefined [#](/creator/twitter::1366500304867401729/influencer_rank)  ### Social Influence [#](/creator/twitter::1366500304867401729/influence) --- **Social category influence** [stocks](/list/stocks) XXX% **Social topic influence** [novartis](/topic/novartis) 3.7%, [$4521t](/topic/$4521t) 1.85%, [$40m](/topic/$40m) 1.85%, [$ptct](/topic/$ptct) 1.85%, [$8604t](/topic/$8604t) 1.85%, [eli lilly](/topic/eli-lilly) 1.85%, [approved](/topic/approved) 1.85%, [breast cancer](/topic/breast-cancer) 1.85%, [eli](/topic/eli) XXXX% **Top accounts mentioned or mentioned by** [@chinchemlett](/creator/undefined) [@chimerix](/creator/undefined) [@jazzpharma](/creator/undefined) [@pumpdotscience](/creator/undefined) [@dr_ponzi](/creator/undefined) [@pyrazoleurea](/creator/undefined) [@betterlifebio](/creator/undefined) [@specterhq](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [PTC Therapeutics, Inc. (PTCT)](/topic/$ptct) [Eli Lilly and Company (LLY)](/topic/eli-lilly) ### Top Social Posts [#](/creator/twitter::1366500304867401729/posts) --- Top posts by engagements in the last XX hours "In this Flash Talk Peter Skewes-Cox presented recent AI-driven advances in high-content screening that are accelerating drug discovery by augmenting and even replacing traditional workflows. Peter emphasized that while HCS once depended on manual processing deep learning methods now allow for a higher degree of automation. Inspired by innovations in natural image classification and autonomous driving AI methods have significantly advanced cellular image interpretation. Generative AI approaches including in silico labeling and profile-conditioned diffusion further extend these capabilities." [X Link](https://x.com/drughunter_com/status/1977751935605191072) [@drughunter_com](/creator/x/drughunter_com) 2025-10-13T15:03Z 10.7K followers, 1142 engagements "Alumis lead candidate ESK-001 is a potential best-in-class allosteric TYK2 inhibitor for immune-mediated diseases like plaque psoriasis and SLE. Just last month Kaken Pharmaceutical inked a $40M+ licensing deal for rights in Japanunderscoring confidence in this promising next-generation TYK2 inhibitor. Read more:" [X Link](https://x.com/drughunter_com/status/1920138003516690463) [@drughunter_com](/creator/x/drughunter_com) 2025-05-07T15:25Z 10.7K followers, 6383 engagements "Votoplam: A CNS-Penetrant HTT pre-mRNA Splice Modulator for the Treatment of Huntingtons Disease Votoplam (PTC518) is an HTT pre-mRNA splice modulator originally developed by PTC Therapeutics and later in-licensed by Novartis currently being evaluated in a Ph. X clinical trial for the treatment of Huntingtons disease. A pioneer in mRNA-targeting small molecules PTC leveraged its splicing platform to discover an orally bioavailable compound capable of lowering levels of mHTT the key driver of HD pathogenesis. Votoplam promotes the inclusion of a pseudoexon in the mHTT mRNA transcript that" [X Link](https://x.com/drughunter_com/status/1974211103266574838) [@drughunter_com](/creator/x/drughunter_com) 2025-10-03T20:33Z 10.7K followers, 2102 engagements "Dordaviprone received FDA accelerated approval for the treatment of DMG (diffuse midline glioma) harboring the H3(K27M) mutation in patients X year old with progressive disease after prior therapy. It is the first FDA-approved systemic therapy specifically for H3(K27M)mutant DMGa disease that primarily affects children and young adultsand the first imipridone from the @Chimerix/@JazzPharma partnership to reach approval. Read more:" [X Link](https://x.com/drughunter_com/status/1977028459051270241) [@drughunter_com](/creator/x/drughunter_com) 2025-10-11T15:08Z 10.7K followers, 3414 engagements "More than XX% of human proteins are still considered undruggable because they lack known or well-defined binding pockets that can be effectively targeted by small molecules. In this Flash Talk Daniel Nomura Professor of Chemical Biology and Molecular Therapeutics will present his groups recent efforts applying chemoproteomic approaches to identify and pharmacologically target novel ligandable hotspots within disease-relevant proteins. Daniel will also highlight how chemoproteomic platforms have expanded the scope of emerging therapeutic modalities including targeted protein degradation and" [X Link](https://x.com/drughunter_com/status/1977834988121780304) [@drughunter_com](/creator/x/drughunter_com) 2025-10-13T20:33Z 10.7K followers, 1537 engagements "ETN029 is a DLL3-targeted macrocyclic peptide with a DOTA chelator enabling theranostics: 111In for imaging and 225Ac for therapy. Single-dose 225Ac-ETN029 drove tumor regression in DLL3-positive CDX models. Ph. X planned for late 2025. Read more:" [X Link](https://x.com/drughunter_com/status/1976026567319884179) [@drughunter_com](/creator/x/drughunter_com) 2025-10-08T20:47Z 10.7K followers, 2545 engagements "The second of a two-part review on CDK4/6 inhibitors focuses on the approved molecules that transformed the treatment of HR+/HER2- breast cancer. Palbociclib (Pfizer) ribociclib (Novartis) and abemaciclib (Eli Lilly) have shown a significant extension in progression-free survival when combined with endocrine therapy. Though all three share a common ATP-competitive binding motif their divergent chemotypes lead to differences in selectivity and tolerability. - palbociclib was the first CDK4/6 inhibitor approved and was optimized for CDK4/6 selectivity - ribociclib achieved 10000 fold" [X Link](https://x.com/drughunter_com/status/1978565063884595697) [@drughunter_com](/creator/x/drughunter_com) 2025-10-15T20:54Z 10.7K followers, 1185 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@drughunter_com drug hunter
drug hunter posts on X about novartis, $4521t, $40m, $ptct the most. They currently have XXXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX +218%
- X Months XXXXXXX +86%
- X Year XXXXXXX +129%
Mentions: X #
- X Week XX +71%
- X Month XX +120%
- X Months XX +19%
- X Year XXX +159%
Followers: XXXXXX #
- X Week XXXXXX +0.13%
- X Month XXXXXX +0.72%
- X Months XXXXXX +5.50%
- X Year XXXXXX +7.30%
CreatorRank: undefined #
Social Influence #
Social category influence stocks XXX%
Social topic influence novartis 3.7%, $4521t 1.85%, $40m 1.85%, $ptct 1.85%, $8604t 1.85%, eli lilly 1.85%, approved 1.85%, breast cancer 1.85%, eli XXXX%
Top accounts mentioned or mentioned by @chinchemlett @chimerix @jazzpharma @pumpdotscience @dr_ponzi @pyrazoleurea @betterlifebio @specterhq
Top assets mentioned Novartis AG (NVS) PTC Therapeutics, Inc. (PTCT) Eli Lilly and Company (LLY)
Top Social Posts #
Top posts by engagements in the last XX hours
"In this Flash Talk Peter Skewes-Cox presented recent AI-driven advances in high-content screening that are accelerating drug discovery by augmenting and even replacing traditional workflows. Peter emphasized that while HCS once depended on manual processing deep learning methods now allow for a higher degree of automation. Inspired by innovations in natural image classification and autonomous driving AI methods have significantly advanced cellular image interpretation. Generative AI approaches including in silico labeling and profile-conditioned diffusion further extend these capabilities."
X Link @drughunter_com 2025-10-13T15:03Z 10.7K followers, 1142 engagements
"Alumis lead candidate ESK-001 is a potential best-in-class allosteric TYK2 inhibitor for immune-mediated diseases like plaque psoriasis and SLE. Just last month Kaken Pharmaceutical inked a $40M+ licensing deal for rights in Japanunderscoring confidence in this promising next-generation TYK2 inhibitor. Read more:"
X Link @drughunter_com 2025-05-07T15:25Z 10.7K followers, 6383 engagements
"Votoplam: A CNS-Penetrant HTT pre-mRNA Splice Modulator for the Treatment of Huntingtons Disease Votoplam (PTC518) is an HTT pre-mRNA splice modulator originally developed by PTC Therapeutics and later in-licensed by Novartis currently being evaluated in a Ph. X clinical trial for the treatment of Huntingtons disease. A pioneer in mRNA-targeting small molecules PTC leveraged its splicing platform to discover an orally bioavailable compound capable of lowering levels of mHTT the key driver of HD pathogenesis. Votoplam promotes the inclusion of a pseudoexon in the mHTT mRNA transcript that"
X Link @drughunter_com 2025-10-03T20:33Z 10.7K followers, 2102 engagements
"Dordaviprone received FDA accelerated approval for the treatment of DMG (diffuse midline glioma) harboring the H3(K27M) mutation in patients X year old with progressive disease after prior therapy. It is the first FDA-approved systemic therapy specifically for H3(K27M)mutant DMGa disease that primarily affects children and young adultsand the first imipridone from the @Chimerix/@JazzPharma partnership to reach approval. Read more:"
X Link @drughunter_com 2025-10-11T15:08Z 10.7K followers, 3414 engagements
"More than XX% of human proteins are still considered undruggable because they lack known or well-defined binding pockets that can be effectively targeted by small molecules. In this Flash Talk Daniel Nomura Professor of Chemical Biology and Molecular Therapeutics will present his groups recent efforts applying chemoproteomic approaches to identify and pharmacologically target novel ligandable hotspots within disease-relevant proteins. Daniel will also highlight how chemoproteomic platforms have expanded the scope of emerging therapeutic modalities including targeted protein degradation and"
X Link @drughunter_com 2025-10-13T20:33Z 10.7K followers, 1537 engagements
"ETN029 is a DLL3-targeted macrocyclic peptide with a DOTA chelator enabling theranostics: 111In for imaging and 225Ac for therapy. Single-dose 225Ac-ETN029 drove tumor regression in DLL3-positive CDX models. Ph. X planned for late 2025. Read more:"
X Link @drughunter_com 2025-10-08T20:47Z 10.7K followers, 2545 engagements
"The second of a two-part review on CDK4/6 inhibitors focuses on the approved molecules that transformed the treatment of HR+/HER2- breast cancer. Palbociclib (Pfizer) ribociclib (Novartis) and abemaciclib (Eli Lilly) have shown a significant extension in progression-free survival when combined with endocrine therapy. Though all three share a common ATP-competitive binding motif their divergent chemotypes lead to differences in selectivity and tolerability. - palbociclib was the first CDK4/6 inhibitor approved and was optimized for CDK4/6 selectivity - ribociclib achieved 10000 fold"
X Link @drughunter_com 2025-10-15T20:54Z 10.7K followers, 1185 engagements